Cargando…

Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant

BACKGROUND: Lipids serve as multifunctional metabolites that have important implications for the pregnant mother and developing fetus. Abnormalities in lipids have emerged as potential risk factors for pregnancy diseases, such as preeclampsia and fetal growth restriction. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartho, Lucy A., Keenan, Emerson, Walker, Susan P., MacDonald, Teresa M., Nijagal, Brunda, Tong, Stephen, Kaitu'u-Lino, Tu'uhevaha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344703/
https://www.ncbi.nlm.nih.gov/pubmed/37421807
http://dx.doi.org/10.1016/j.ebiom.2023.104704
_version_ 1785072917274427392
author Bartho, Lucy A.
Keenan, Emerson
Walker, Susan P.
MacDonald, Teresa M.
Nijagal, Brunda
Tong, Stephen
Kaitu'u-Lino, Tu'uhevaha J.
author_facet Bartho, Lucy A.
Keenan, Emerson
Walker, Susan P.
MacDonald, Teresa M.
Nijagal, Brunda
Tong, Stephen
Kaitu'u-Lino, Tu'uhevaha J.
author_sort Bartho, Lucy A.
collection PubMed
description BACKGROUND: Lipids serve as multifunctional metabolites that have important implications for the pregnant mother and developing fetus. Abnormalities in lipids have emerged as potential risk factors for pregnancy diseases, such as preeclampsia and fetal growth restriction. The aim of this study was to assess the potential of lipid metabolites for detection of late-onset preeclampsia and fetal growth restriction. METHODS: We used a case-cohort of 144 maternal plasma samples at 36 weeks’ gestation from patients before the diagnosis of late-onset preeclampsia (n = 22), delivery of a fetal growth restricted infant (n = 55, defined as <5th birthweight centile), gestation-matched controls (n = 72). We performed liquid chromatography-tandem mass spectrometry (LC-QQQ) -based targeted lipidomics to identify 421 lipids, and fitted logistic regression models for each lipid, correcting for maternal age, BMI, smoking, and gestational diabetes. FINDINGS: Phosphatidylinositol 32:1 (AUC = 0.81) and cholesterol ester 17:1 (AUC = 0.71) best predicted the risk of developing preeclampsia or delivering a fetal growth restricted infant, respectively. Five times repeated five-fold cross validation demonstrated the lipids alone did not out-perform existing protein biomarkers, soluble tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) for the prediction of preeclampsia or fetal growth restriction. However, lipids combined with sFlt-1 and PlGF measurements improved disease prediction. INTERPRETATION: This study successfully identified 421 lipids in maternal plasma collected at 36 weeks’ gestation from participants who later developed preeclampsia or delivered a fetal growth restricted infant. Our results suggest the predictive capacity of lipid measurements for gestational disorders holds the potential to improve non-invasive assessment of maternal and fetal health. FUNDING: This study was funded by a grant from 10.13039/501100000925National Health and Medical Research Council.
format Online
Article
Text
id pubmed-10344703
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103447032023-07-15 Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant Bartho, Lucy A. Keenan, Emerson Walker, Susan P. MacDonald, Teresa M. Nijagal, Brunda Tong, Stephen Kaitu'u-Lino, Tu'uhevaha J. eBioMedicine Articles BACKGROUND: Lipids serve as multifunctional metabolites that have important implications for the pregnant mother and developing fetus. Abnormalities in lipids have emerged as potential risk factors for pregnancy diseases, such as preeclampsia and fetal growth restriction. The aim of this study was to assess the potential of lipid metabolites for detection of late-onset preeclampsia and fetal growth restriction. METHODS: We used a case-cohort of 144 maternal plasma samples at 36 weeks’ gestation from patients before the diagnosis of late-onset preeclampsia (n = 22), delivery of a fetal growth restricted infant (n = 55, defined as <5th birthweight centile), gestation-matched controls (n = 72). We performed liquid chromatography-tandem mass spectrometry (LC-QQQ) -based targeted lipidomics to identify 421 lipids, and fitted logistic regression models for each lipid, correcting for maternal age, BMI, smoking, and gestational diabetes. FINDINGS: Phosphatidylinositol 32:1 (AUC = 0.81) and cholesterol ester 17:1 (AUC = 0.71) best predicted the risk of developing preeclampsia or delivering a fetal growth restricted infant, respectively. Five times repeated five-fold cross validation demonstrated the lipids alone did not out-perform existing protein biomarkers, soluble tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) for the prediction of preeclampsia or fetal growth restriction. However, lipids combined with sFlt-1 and PlGF measurements improved disease prediction. INTERPRETATION: This study successfully identified 421 lipids in maternal plasma collected at 36 weeks’ gestation from participants who later developed preeclampsia or delivered a fetal growth restricted infant. Our results suggest the predictive capacity of lipid measurements for gestational disorders holds the potential to improve non-invasive assessment of maternal and fetal health. FUNDING: This study was funded by a grant from 10.13039/501100000925National Health and Medical Research Council. Elsevier 2023-07-06 /pmc/articles/PMC10344703/ /pubmed/37421807 http://dx.doi.org/10.1016/j.ebiom.2023.104704 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Bartho, Lucy A.
Keenan, Emerson
Walker, Susan P.
MacDonald, Teresa M.
Nijagal, Brunda
Tong, Stephen
Kaitu'u-Lino, Tu'uhevaha J.
Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title_full Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title_fullStr Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title_full_unstemmed Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title_short Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
title_sort plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344703/
https://www.ncbi.nlm.nih.gov/pubmed/37421807
http://dx.doi.org/10.1016/j.ebiom.2023.104704
work_keys_str_mv AT bartholucya plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT keenanemerson plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT walkersusanp plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT macdonaldteresam plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT nijagalbrunda plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT tongstephen plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant
AT kaituulinotuuhevahaj plasmalipidsaredysregulatedprecedingdiagnosisofpreeclampsiaordeliveryofagrowthrestrictedinfant